The 2021 study by Fukumoto et al. showed that ARID2 knockout sensitizes melanoma to immune checkpoint inhibitors (anti-PD-L1 treatment), which is associated with an increase in the infiltration of CD8+ cytotoxic T cells. The gene discussed is ARID2; the disease is melanoma.